Overview

First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

Status:
NOT_YET_RECRUITING

Trial end date:
2029-09-30

Target enrollment:

Participant gender:

Summary

This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided mCRC.

Phase:

PHASE3

Details

Lead Sponsor:

Meng Qiu

Treatments:

Cetuximab